Haine

Charles Haine, Claremont, CA US

Patent application number	Description	Published
20100016264	TREATMENT FOR DRY EYE USING TESTOSTERONE AND PROGESTAGEN - The present invention comprises a composition and methods for treating eye conditions using a composition having a therapeutically effective amount of a progestagen, or a therapeutically effective amount of a progestagen with a testosterone; and pharmaceutically acceptable carrier, wherein the composition is applied to the palpebral part of the eye and/or ocular surface.	01-21-2010

Patent application number	Description	Published
20100308701	Memorabilia display case - A memorabilia display case is adapted to store and display the two and/or three dimensional articles. The display case includes a front frame member and a back frame member. The front frame member is vertically and horizontally adjustable through a hinge mechanism for securely accommodating a glass panel in a first recessed portion defined on the front frame member. The back frame member includes a mounting panel that is permanently screwed into the back frame member. The mounting panel is adapted to mount three dimensional articles. The back frame member defines a groove portion that includes a pair of spring leafs that can be fitted and locked into a second recessed portion defined on the front frame member to define a locking arrangement for the display case. The back frame member includes a hanging mechanism adapted to facilitate mounting means for the case.	12-09-2010

Patent application number	Description	Published
20090117155	TREATMENT OF HIV-1 BY MODULATION OF VPR ACTIVATION OF THE M-CSF PROMOTER - Macrophage colony-stimulating factor (M-CSF) is important for human immunodeficiency virus-type 1 (HIV-1) infection, replication and survival of infected cells. The mechanism(s) by which HIV-1 infection increases M-CSF production are, however, poorly understood. Here, we report that HIV-1 Vpr enhances M-CSF promoter activity and production in primary human monocytes and macrophages. Vpr activates M-CSF transcription through four C/EBP beta binding sites present within the M-CSF promoter, possibly through increased phosphorylation of C/EBP beta. RU486 (mifepristone) blocked Vpr-mediated up-regulation of M-CSF, suggesting that Vpr activates M-CSF promoter activity via the glucocorticoid pathway. The invention provides new avenues for therapeutic interventions in HIV-1 infection and other diseases involving M-CSF dysregulation (including malignancy, osteoporosis, autoimmune disorders, arthritis, and obesity) using glucocorticoid antagonists and modulators of C/EBP beta activity.	05-07-2009